Kolkata-based diagnostics chain running pathology & radiology labs, collection centres and clinics across East and North-East India.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 7 | 7 | 7 | 7 | 7 | 10 | 10 | 10 |
| Reserves | 111 | 118 | 141 | 147 | 171 | 201 | 220 | 234 |
| Borrowings | 13 | 18 | 21 | 99 | 92 | 89 | 118 | 130 |
| Other Liabilities | 42 | 28 | 32 | 28 | 30 | 33 | 32 | 73 |
| Total Liabilities | 173 | 171 | 201 | 281 | 300 | 334 | 380 | 448 |
| AssetsFixed Assets | 128 | 119 | 119 | 195 | 212 | 223 | 277 | 316 |
| CWIP | 0 | 0 | 1 | 2 | 1 | 11 | 2 | 35 |
| Investments | 5 | 5 | 0 | 0 | 0 | 1 | 0 | 0 |
| Other Assets | 39 | 46 | 80 | 84 | 87 | 99 | 101 | 97 |
| Total Assets | 173 | 171 | 201 | 281 | 300 | 334 | 380 | 448 |
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 31 | 24 | 42 | 44 | 60 | 63 | 82 |
| Cash from Investing | -20 | -28 | -44 | -21 | -35 | -40 | -52 |
| Cash from Financing | -10 | 3 | 1 | -24 | -25 | -24 | -29 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — |
| Free Cash Flow | 15 | 8 | 23 | 32 | 18 | 21 | 15 |
| FCF Margin | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (40.0×) and current (43.4×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 1.4% growth and a 40× exit, ₹268 only delivers your return if you pay ₹110. The price is currently baking in 19% growth.
EPS grows 1.4%/yr for 5 years, then fades to 6% over 2, exits at 40×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 1.4% | 6.27 |
| FY28 | 1.4% | 6.35 |
| FY29 | 1.4% | 6.44 |
| FY30 | 1.4% | 6.53 |
| FY31 | 1.4% | 6.62 |
| FY32 | 3.7% ·fade | 6.87 |
| FY33 | 6.0% ·fade | 7.28 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.